ロード中...
Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
PURPOSE: To determine tolerability and for the first time explore efficacy of bendamustine plus rituximab (BR) in multiply relapsed/refractory hairy cell leukemia (HCL), using 2 different dose levels of bendamustine. EXPERIMENTAL DESIGN: HCL patients with ≥2 prior therapies requiring treatment recei...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3861900/ https://ncbi.nlm.nih.gov/pubmed/24097860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1848 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|